Has Nneka Ufere, MD received payments from drug or device companies?

Yes. Drug and device makers reported $152,700 in general payments to Nneka Ufere, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nneka Ufere, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nneka Ufere, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nneka Ufere, MD

Gastroenterology · Boston, MANPI 1356603153

Payments from drug & device makers

What this record shows

This record is dominated by grants: $150,000 of the $152,700 with a category attached, or 98.2%. Novo Nordisk accounts for 65.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $125,000 and has fallen 97.8% since, to $2,700 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$152,700in general payments, 2019–2025

Across 6 payments — averaging $25,450 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$100K
Pfizer$50K
Mallinckrodt Hospital Products Inc.$3K

What the payments were for

Consulting fees$2,7002%
Grants$150,00098%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	4	$100,000
Pfizer	1	$50,000
Mallinckrodt Hospital Products Inc.	1	$2,700

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TERLIVAZ$2,700

How this compares

$152,700 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$28,768

Medicare patients

113

Services billed

215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	23	$315
Carvedilol	12	$91

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Boston

Hiroyuki AiharaBoston$728K
Jessica AllegrettiBoston$696K
John LeungBoston$682K
Ramnik XavierBoston$567K
Adam CheifetzBoston$512K
Carlo TraversoBoston$447K
Tyler BerzinBoston$215K
Marvin RyouBoston$162K
Christopher ThompsonBoston$127K
Scott SnapperBoston$126K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →